Recover legacy radium-226 sources worldwide as the feedstock for actinium-225
Thousands of old radium sources sit in hospital and industrial storage. They are exactly the raw material needed to make actinium-225, the scarcest cancer isotope.
Actinium-225 supply from thorium-229 generators (the legacy US and Russian stockpiles) is limited to tens of curies a year, far short of projected demand for alpha radioligand therapy. Accelerator routes (radium-226 irradiated in cyclotrons, linacs or via spallation at TRIUMF) scale with radium feedstock. Radium-226 exists in large quantities in disused brachytherapy sources, industrial gauges and uranium mill tailings, currently classed as waste and expensive to store. The proposal is a coordinated recovery, purification and target-fabrication programme run with the IAEA and national nuclear agencies, offering source holders free disposal in exchange for the material.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Pages like this
not linked directly; found by shared links- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 DOTATATE, Actinium-225 PSMA agents, Targeted alpha therapy, Radioligand therapy (beta emitters).
- IdeaFund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211
Shares Orano Med, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
- IdeaA global medical isotope supply observatory with forecasts and shortage alerts
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Manufacturing cost and time for living and radioactive medicines.
- RoadmapRadiopharmaceutical roadmap: iodine → lutetium → actinium
Shares TerraPower Isotopes, Actinium-225 DOTATATE, Orano Med, Actinium-225 PSMA agents.
- TechnologyAlpha-emitter nanogenerators and daughter trapping
Shares TerraPower Isotopes, Targeted alpha therapy, Radioligand therapy (beta emitters).
- TechnologyTherapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)
Shares TerraPower Isotopes, Orano Med, Targeted alpha therapy, Radioligand therapy (beta emitters).
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Radioligand therapy (beta emitters).
- CompanyRayzeBio (BMS)